[HTML][HTML] Semaglutide and cardiovascular outcomes in obesity without diabetes
AM Lincoff, K Brown-Frandsen… - … England Journal of …, 2023 - Mass Medical Soc
… 8 and diabetes 9,10 is standard evidence-based practice, the concept of treating obesity to
reduce the risk of cardiovascular … for overweight or obesity improve cardiovascular outcomes. …
reduce the risk of cardiovascular … for overweight or obesity improve cardiovascular outcomes. …
[HTML][HTML] Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in …
I Lingvay, J Deanfield, SE Kahn, PE Weeke… - Diabetes …, 2024 - diabetesjournals.org
… whether the cardiovascular outcomes of semaglutide versus … of semaglutide versus placebo
on cardiovascular outcomes … whether the cardiovascular benefits of semaglutide are only …
on cardiovascular outcomes … whether the cardiovascular benefits of semaglutide are only …
[HTML][HTML] Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design
… outcome and demonstrates reduced CVD events in persons with obesity and prior CVD
but without diabetes, semaglutide 2.4 mg once weekly treatment should inform obesity …
but without diabetes, semaglutide 2.4 mg once weekly treatment should inform obesity …
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
SP Marso, SC Bain, A Consoli… - … England Journal of …, 2016 - Mass Medical Soc
… The primary composite outcome was the first occurrence of cardiovascular death, nonfatal
… We hypothesized that semaglutide would be noninferior to placebo for the primary outcome. …
… We hypothesized that semaglutide would be noninferior to placebo for the primary outcome. …
Cardiovascular outcome trials in obesity: a review
JPH Wilding, S Jacob - Obesity reviews, 2021 - Wiley Online Library
… liraglutide and semaglutide improved CV and renal outcomes with no apparent
differences across BMI groups. However, subgroup analysis of the EMPA-REG OUTCOME (empagliflozin…
differences across BMI groups. However, subgroup analysis of the EMPA-REG OUTCOME (empagliflozin…
Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
I Lingvay, K Brown‐Frandsen, HM Colhoun… - …, 2023 - Wiley Online Library
… administered dose of 2.4 mg semaglutide on CV outcomes compared with placebo in people
without diabetes but who were living with overweight or obesity and who suffered from a …
without diabetes but who were living with overweight or obesity and who suffered from a …
Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
M Husain, AL Birkenfeld, M Donsmark… - … England Journal of …, 2019 - Mass Medical Soc
… We assessed cardiovascular outcomes of once-daily oral semaglutide in an event-driven,
randomized, double-blind, placebo-controlled trial involving patients at high cardiovascular …
randomized, double-blind, placebo-controlled trial involving patients at high cardiovascular …
[PDF][PDF] SELECT semaglutide to improve outcomes in patients with obesity and cardiovascular disease, also without diabetes
G Gajos - Cardiology Journal, 2024 - journals.viamedica.pl
… — and to lower the risk of cardiovascular disease in patients with diabetes [1, 3]. Therefore,
I … SELECT study (Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes) …
I … SELECT study (Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes) …
[HTML][HTML] Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
… In the SELECT cardiovascular outcomes trial, semaglutide showed a 20% reduction in …
established CVD and overweight or obesity but without diabetes. In SELECT, semaglutide was …
established CVD and overweight or obesity but without diabetes. In SELECT, semaglutide was …
Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
Y Deng, A Park, L Zhu, W Xie… - Therapeutic advances in …, 2022 - journals.sagepub.com
… with diabetes. While few reviews focused on obese/overweight individuals without diabetes,
we aimed to perform a systematic review of semaglutide and liraglutide in randomized …
we aimed to perform a systematic review of semaglutide and liraglutide in randomized …